

Table S1 Univariate and multivariate analyses of progression-free survival

Variables	Univariate			Multivariate		
	HR	95% CI	P	HR	95% CI	P
Age (years)						
<60 vs. ≥60	0.766	0.295–1.984	0.58			NI
Sex						
Male vs. female	1.167	0.388–3.506	0.78			NI
ECOG performance status						
0 vs. 1	1.187	0.491–2.871	0.70			NI
BMI, kg/m ²						
<25.0 vs. ≥25.0	2.004	0.664–6.047	0.22			NI
Location of primary tumor						
Gastric vs. GEJ	0.318	0.042–2.384	0.27			NI
Organs with metastasis						
≤2 vs. >2	0.856	0.352–2.081	0.73			NI
Lymph node metastasis						
Yes vs. no	1.274	0.422–3.842	0.67			NI
Liver metastasis						
Yes vs. no	2.610	1.073–6.352	0.03*	1.904	0.656–5.527	0.24
Lung metastasis						
Yes vs. no	0.643	0.149–2.775	0.55			NI
Previous gastrectomy						
Yes vs. no	1.200	0.401–3.589	0.74			NI
PD-L1 CPS expression						
>1 vs. ≤1 & UN	0.625	0.251–1.555	0.31			NI
Weight loss						
Yes vs. no	0.998	0.417–2.389	0.99			NI
Anemia						
Yes vs. no	1.415	0.536–3.734	0.48			NI
Albumin						
Decreased vs. normal	3.828	1.231–11.902	0.02*	3.683	1.142–11.883	0.03*
Carcinoembryonic antigen						
Elevated vs. normal	1.469	0.616–3.500	0.39			NI
Carbohydrate antigen 19-9						
Elevated vs. normal	2.465	1.013–5.997	0.047*	1.640	0.557–4.825	0.37
Carbohydrate antigen 125						
Elevated vs. normal	1.387	0.564–3.411	0.48			NI
Fibrinogen						
Elevated vs. normal	0.739	0.309–1.769	0.50			NI
Lactate dehydrogenase						
Elevated vs. normal	1.265	0.461–3.470	0.65			NI
D dimer						
Elevated vs. normal	3.072	0.708–13.331	0.13			NI

*, P<0.05. HR, hazard ratio; CI, confidence interval; NI, not included; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; GEJ, gastroesophageal junction; PD-L1, programmed death-ligand 1; CPS, combined positive score; UN, unknown.

Table S2 Univariate and multivariate analyses of overall survival

Variables	Univariate			Multivariate		
	HR	95% CI	P	HR	95% CI	P
Age (years)						
<60 vs. ≥60	0.587	0.222–1.555	0.28			NI
Sex						
Male vs. female	1.257	0.414–3.816	0.69			NI
ECOG performance status						
0 vs. 1	0.924	0.376–2.269	0.86			NI
BMI, kg/m ²						
<25.0 vs. ≥25.0	1.442	0.474–4.387	0.52			NI
Location of primary tumor						
Gastric vs. GEJ	0.439	0.058–3.323	0.43			NI
Organs with metastasis						
≤2 vs. >2	0.810	0.330–1.992	0.65			NI
Lymph node metastasis						
Yes vs. no	1.107	0.363–3.377	0.86			NI
Liver metastasis						
Yes vs. no	2.459	0.998–6.063	0.051			NI
Lung metastasis						
Yes vs. no	0.779	0.179–3.380	0.74			NI
Previous gastrectomy						
Yes vs. no	1.129	0.374–3.408	0.83			NI
PD-L1 CPS expression						
>1 vs. ≤1 & UN	0.704	0.279–1.774	0.46			NI
Weight loss						
Yes vs. no	1.227	0.506–2.974	0.65			NI
Anemia						
Yes vs. no	1.076	0.408–2.838	0.88			NI
Albumin						
Decreased vs. normal	2.995	1.054–8.507	0.04*	2.404	0.916–6.307	0.08
Carcinoembryonic antigen						
Elevated vs. normal	1.651	0.665–4.102	0.28			NI
Carbohydrate antigen 19-9						
Elevated vs. normal	2.625	1.034–6.664	0.042*	2.798	0.941–8.323	0.06
Carbohydrate antigen 125						
Elevated vs. normal	1.790	0.698–4.589	0.23			NI
Fibrinogen						
Elevated vs. normal	0.805	0.332–1.951	0.63			NI
Lactate dehydrogenase						
Elevated vs. normal	1.092	0.391–3.049	0.87			NI
D dimer						
Elevated vs. normal	2.188	0.505–9.480	0.30			NI

*, P<0.05. HR, hazard ratio; CI, confidence interval; NI, not included; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; GEJ, gastroesophageal junction; PD-L1, programmed death-ligand 1; CPS, combined positive score; UN, unknown.